Cardiff Oncology, Inc. will be holding a conference call on May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego to discuss their financial results for the first quarter ended March 31, 2024 and provide updates on their clinical programs targeting various indications such as colorectal cancer, pancreatic cancer, small cell lung cancer, and triple negative breast cancer.
The company’s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics to target tumor vulnerabilities and deliver superior clinical benefit. During the conference call, Cardiff Oncology will provide insights into their financial performance and discuss the progress of their clinical trials.
Interested investors can listen to the live conference call by using the webcast link in the “Investors” section of the company’s website. A replay of the call will be available in the investor relations section on the website following its completion. For more information about Cardiff Oncology and their clinical programs, visit their website at
For any inquiries, please contact James Levine, Chief Financial Officer of Cardiff Oncology at (858) 952-7670 or via email at [jlevine@cardiffoncology]. For investor inquiries, reach out to Kiki Patel from Gilmartin Group at (332) 895-3225 or email [Kiki@gilmartinir]. For media inquiries, contact Grace Spencer from Taft Communications at (609) 583-1151 or email [grace@taftcommunications].